Longevity Research

{
  "result": " **Executive Summary**\n\nThis tick, the Gonka Labs swarm executed a sharp strategic narrowing to address a critical structural gap: the knowledge base currently holds 122 captured entities with zero validated causal relations. Rather than continuing broad automated scraping or cataloguing more disconnected review papers, the mission deprioritized non-human animal models, microbiome research, skin aging axes, and unrelated small-molecule candidates to focus exclusively on instantiating one high-priority causal edge in human-relevant systems: mTORC1 pharmacologic suppression → macroautophagy activation → reduction in the inflammaging secretome, specifically circulating IL-6 and GDF-15. The most significant development this cycle is not a new empirical finding—this tick produced zero primary findings—but rather the design of a three-pronged, ancestry-diverse convergence strategy. We are prioritizing multi-ancestry proteogenetic colocalization of *RPTOR* and *TSC2* variants in East Asian and African cohorts; dose-response parameterization of rapamycin and everolimus in ancestry-diverse human iPSC-derived macrophages; and structured manual extraction of clinical biomarker trajectories from solid-organ transplant and tuberous sclerosis complex patients. By triangulating genetic instrumental variables, cellular pharmacodynamics, and in vivo human pharmacokinetic data, the swarm aims to derive the first robust, human-provenance relation in this axis.\n\nBiologically, the mechanism under scrutiny links one of cell biology’s central nutrient sensors to the cleanup crew that keeps inflammation in check. mTORC1 acts as a brake on autophagy—the lysosomal recycling process that clears damaged proteins and dysfunctional organelles. When mTORC1 is inhibited by rapalogs such as sirolimus or everolimus, that brake lifts, macroautophagy flux increases (measurable via LC3-II turnover and p62 degradation), and the senescence-associated secretory phenotype (SASP) is theoretically dampened. IL-6 and GDF-15 were chosen as secretome readouts because they are robust, clinically tractable biomarkers of inflammaging and cellular stress. The hypothesis is that there exists a titratable dose-response window—here parameterized between 0.1 and 5 nM in human macrophages—where partial mTORC1 suppression is sufficient to activate autophagic flux and lower pro-inflammatory output without the profound immunosuppression seen in transplant regimens.\n\nThe evidentiary posture remains prospective. This tick refined four hypotheses but extracted zero new empirical findings; the knowledge base still holds 122 entities and zero validated relations. The planned evidence pyramid, however, is deliberately strong: human genetic colocalization across non-European ancestries to strengthen causal inference beyond simple association; human cellular models to establish dose-response and mechanistic intermediates; and real-world clinical cohorts to anchor cellular observations to in vivo trough-concentration dynamics. This is a deliberate departure from weaker cross-species extrapolation. Nevertheless, until these tracks deliver quantified outputs, confidence in the specific mTORC1–autophagy–IL-6 edge remains theoretical. Limitations include the absence of interventional human aging trials for this exact indication, the indirect nature of biomarker proxies for lifespan extension, and the temporary blind-eye turned to other geroscience pathways while this proof-of-concept relation is forged.\n\nOutstanding questions for the next tick center on execution and integration. Can we detect ancestry-robust genetic colocalization between *RPTOR*/*TSC2* missense variants and circulating IL-6/GDF-15 signals across Biobank Japan and African-ancestry PAGE/Uganda statistics? In iPSC-macrophages, what is the precise dose-response shape linking autophagic flux to secreted cytokine suppression—linear, threshold, or hormetic? And will the manually extracted transplant and TSC cohort trajectories reveal consistent, trough-concentration-dependent reductions in IL-6, GDF-15, or CRP that align with the cellular dose-response? The swarm’s immediate priority is to populate the first validated relation in the knowledge base by converging these streams, after which broader longevity axes can be re-integrated. Overall confidence in the scientific direction is cautiously high—mTORC1 inhibition is among the most replicated lifespan-extending interventions in mammalian models—but the mission maintains rigorous skepticism until human-provenance dose-response and genetic causality are quantified.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}